4.4 Article

An experimental medicine study of the phosphodiesterase-4 inhibitor, roflumilast, on working memory-related brain activity and episodic memory in schizophrenia patients

期刊

PSYCHOPHARMACOLOGY
卷 238, 期 5, 页码 1279-1289

出版社

SPRINGER
DOI: 10.1007/s00213-018-5134-y

关键词

PDE4; Cognition; Schizophrenia; ‘ Cognitive enhancement’ fMRI; Memory; ‘ PDE4 inhibition’ CIAS; Roflumilast

资金

  1. Medical Research Council [G0901868] Funding Source: Medline
  2. Takeda Pharmaceuticals U.S.A. (US) [n/a] Funding Source: Medline
  3. Wellcome Trust Funding Source: Medline

向作者/读者索取更多资源

The study investigated the potential of using roflumilast to improve cognitive functioning in schizophrenia patients. Results showed that higher doses of roflumilast significantly improved verbal memory, but had no significant impact on working memory.
Rationale Schizophrenia is associated with impairments in cognitive functioning yet there are no approved drugs to treat these deficits. Objectives Based on animal models, we investigated the potential for roflumilast, a selective inhibitor of phosphodiesterase type 4 (PDE4), to improve cognition, which may act by increasing intracellular cyclic adenosine monophosphate in brain regions underlying cognitive deficits in schizophrenia. Methods This study consisted of a randomised, double-blind, placebo-controlled, crossover design involving 15 schizophrenia patients. In 3 treatment periods, patients were given 8 days of placebo or one of the two doses of roflumilast (100 and 250 mu g daily) with 14 days of washout between treatments. The primary endpoints were dorsolateral prefrontal cortex (DLPFC) activation during a visuospatial working memory task measured with fMRI on dosing day 8 and verbal memory and working memory performance change from baseline to day 8. Least square mean change scores were calculated for behavioural outcomes; fMRI data were analysed in SPM12 with bilateral DLPFC as regions of interest. Results Verbal memory was significantly improved under 250 mu g roflumilast (effect size (ES) = 0.77) compared to placebo. fMRI analyses revealed that increasing dose of roflumilast was associated with reduction of bilateral DLPFC activation during working memory compared to placebo, although this was not statistically significant (ES = 0.31 for the higher dose). Working memory was not improved (ES = 0.03). Conclusions Results support the mechanistic validation of potential novel strategies for improving cognitive dysfunction in schizophrenia and suggest that PDE4 inhibition may be beneficial for cognitive dysfunction in schizophrenia.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据